Abstract: A method of delivering an active agent to a target tissue, particularly neoplastic tissue, vascular anomaly or tumor tissue, in a vertebrate subject. The method includes the steps of exposing the target tissue to ionizing radiation; and administering a delivery vehicle to the vertebrate subject before, after, during, or combinations thereof, exposing the target tissue to the ionizing radiation. The delivery vehicle includes the active agent and delivers the agent to the target tissue. Exemplary delivery vehicles include platelets; leukocytes; proteins or peptides which bind activated platelets; antibodies which bind activated platelets; microspheres coated with proteins or peptides which bind activated platelets; liposomes conjugated to platelets, leukocytes, proteins or peptides which bind activated platelets, or antibodies which bind activated platelets; and combinations thereof.
Abstract: A method for generating adenoviral vectors from polynucleotides such as plasmids wherein there occurs recombinase-mediated transfer of an adenoviral ITR and terminal proteins bound to the ITR to a plasmid, thus enabling the plasmid to replicate as an adenoviral vector. Such method enables the rapid generation of adenoviral vectors at high titers from plasmids without the use of selectable markers and screening procedures. Such method enables the rapid generation of adenoviral vectors devoid of adenovirus backbone genes. The method also may be employed to generate hybrid adenoviral-retroviral vectors that convert transduced cells into producer cells that produce retroviral vectors to effect high level, permanent genetic modification of cells in vivo.
Abstract: Insect viruses capable of killing at least one target insect pest quicker than previously described viruses and methods for conferring that phenotype of faster killing are provided. Further improvement in the speed of killing is obtained when the virus of this invention also contains a nonfunctional egt gene to reduce feeding by the infected larvae, inhibit growth and further mediate the earlier death of the infected insect and/or it also contains and expresses a DNA sequence encoding an insect-specific toxin. The faster killing phenotype is achieved by inactivating an ORF 603 of AcMNPV or an ORF 603 homolog of a different species of baculovirus. Improved insecticidal compositions and improved methods of controlling insects are also included within the scope of this invention.
Type:
Grant
Filed:
January 12, 1999
Date of Patent:
December 5, 2000
Assignees:
University of Georgia Research Foundation, American Cyanamid Corporation
Inventors:
Lois K. Miller, Bruce C. Black, Peter M. Dierks, Nancy C. Fleming
Abstract: Recombinational cloning is provided by the use of nucleic acids, vectors and methods, in vitro and in vivo, for moving or exchanging segments of DNA molecules using engineered recombination sites and recombination proteins to provide chimeric DNA molecules that have the desired characteristic(s) and/or DNA segment(s).
Abstract: The invention relates to new artificial tissues which comprise three-dimensional extracellular matrixes (ECM) in cross-linkable structures, cell interaction systems for inducing artificial three-dimensional tissues and which comprise genetically manipulated cells releasing immunosuppressive or cell-differentiating factors. The tissues according to the invention are suitable for producing vital transplants and for establishing models of diseases.
Type:
Grant
Filed:
March 16, 1999
Date of Patent:
November 7, 2000
Inventors:
Michael Sittinger, Olaf Schultz, Gerd R. Burmester, Thomas E. M. Haupl
Abstract: The invention relates to sequences of nucleotides of bacteria, particularly Gram positive bacteria such as bacteria of the Bacillus type and more particularly sequences of nucleotides of the gene CryIIIA for the control of the expression of DNA sequences in a cellular host. The invention relates particularly to an expression system comprising a DNA sequence susceptible of being involved in the control of the expression of a coding sequence of nucleotides. Said DNA sequence comprises a promoter, as well as a sequence of nucleotides called "downstream region", situated between the promoter and the coding sequence of the gene to be expressed, and susceptible of acting at the post-transcriptional level during the expression of the gene. Preferably, the downstream region comprises a nucleotide sequence S2 comprising an essentially complementary region at the extremity 3' of the RNA 16S of the ribosomes of Bacillus type bacteria.
Type:
Grant
Filed:
December 20, 1995
Date of Patent:
October 31, 2000
Assignees:
Institut Pasteur, Institut Nationale de la Recherche Agronomique
Abstract: Methods and vectors (both DNA and retroviral) are provided for the construction of a Library of mutated cells. The Library will preferably contain mutations in essentially all genes present in the genome of the cells. The nature of the Library and the vectors allow for methods of screening for mutations in specific genes, and for gathering nucleotide sequence data from each mutated gene to provide a database of tagged gene sequences. Such a database provides a means to access the individual mutant cell clones contained in the Library. The invention includes the described Library, methods of making the same, and vectors used to construct the Library. Methods are also provided for accessing individual parts of the Library either by sequence or by pooling and screening. The invention also provides for the generation of non-human transgenic animals which are mutant for specific genes as isolated and generated from the cells of the Library.
Type:
Grant
Filed:
October 4, 1996
Date of Patent:
October 24, 2000
Assignee:
Lexicon Graphics Incorporated
Inventors:
Arthur Sands, Glenn Friedrich, Brian Zambrowicz, Allan Bradley
Abstract: Methods and compositions related to HIV are disclosed. Using the methods of the present invention, nucleoside analogs may be screened for the ability to be incorporated by reverse transcriptase of human immunodeficiency virus ("HIV RT") and cause incorrect base pairing. Progressive mutation of the virus by such nucleoside analogs renders it non-viable.
Abstract: The invention provides platinum-based probe compounds having the structure: ##STR1## wherein: Pt is a platinum atom, PROBE is a probe biomolecule for associating to a target biomolecule, M is a detectable marker moiety, and X and Y are stabilizing substituents. Also provided are platinum-based labeling compounds having the structure: ##STR2## wherein: Pt is a platinum atom, M is a detectable marker moiety, A is a displaceable leaving group, and X and Y are stabilizing substituents. The invention further provides platinum-based linker compounds having the structure: ##STR3## wherein: Pt is a platinum atom, A and B are the same or different reactive moieties, and X and Y are stabilizing substituents. Other Pt.sup.II and Pt.sup.IV compounds are also provided. Moreover, the invention provides methods for the preparation and use of these compounds, as well as diagnostic kits which contain the compounds.
Type:
Grant
Filed:
August 10, 1998
Date of Patent:
October 17, 2000
Assignee:
Kreatech Diagnostics
Inventors:
Hendrik J. Houthoff, Jan Reedijk, Tinka Jelsma, Remco Maria Van Es, Franciscus Michiel van den Berg, Edwin Leo Mario Lempers, Marieke Johanna Bloemink
Abstract: The present invention relates to a novel method for the production of short chain polypeptides, including polypeptides having up to 3 disulfide bonds and/or structures rich in basic amino acid residues, and open structured short chain polypeptides, e.g. glucagon, glucagon like peptides and their functional analogues, in genetically modified yeast cells, said genetically modified yeast cells, and a method for the preparation of said yeast cells.
Type:
Grant
Filed:
July 7, 1997
Date of Patent:
August 29, 2000
Assignee:
Novo Nordisk A/S
Inventors:
Michi Egel-Mitani, Jakob Brandt, Knud Vad
Abstract: DNA constructs and methods for conducting site-specific recombination in plants is described. The method utilizes FLP recombinase to excise a region of DNA flanked by a pair of directly repeated site-specific recombination sequences which are capable of interacting with a FLP recombinase.
Abstract: Cloning systems useful for the isolation of recombinant nucleic acid are disclosed in which the recombination of cloning-system nucleic acid and foreign nucleic acid is linked to the expression of a moiety on the surface of a host organism, the moiety being a first member of a binding pair. When recombination occurs between the nucleic acid and the foreign nucleic acid, the moiety is expressed on the surface of the host organism. The isolation of recombinant nucleic acid is then performed by attaching a second member of the binding pair to a solid support and contacting the host organism with the support. When the first member of the binding pair is expressed on the surface of the host organism, the host organism binds to the second member of the binding pair attached to the solid support, thereby selectively isolating those organisms.
Type:
Grant
Filed:
January 11, 1996
Date of Patent:
August 8, 2000
Assignee:
The Perkin-Elmer Corporation
Inventors:
John A. Bridgham, John Brandis, John Leong, Paul D. Hoeprich, Jr., Charles L. Sloan, Roger A. O'Neill
Abstract: A noncloning method for expressing a gene of interest in a mammalian host cell is disclosed. The invention utilizes three basic individual elements: (1) a promoter element; (2) at least one gene of interest; and (3) a selectable marker cassette which includes in 5' to 3' order, an internal ribosome entry site ("IRES"), at least one gene coding for a selectable marker, and a transcription termination sequence. The three individual elements are cotransfected into a mammalian host cell where they become operably linked such that expression of the selectable marker gene(s) necessarily requires coexpression of the gene of interest.
Abstract: An isothermal transcription based amplification assay for MDC RNA uses primer combinations for sequences within the MDC gene. A quantitative control uses a mutant RNA for comparison.
Type:
Grant
Filed:
January 9, 1998
Date of Patent:
July 25, 2000
Assignee:
Akzo Nobel N.V.
Inventors:
Joseph Romano, Ranajit Pal, Roxanne Shurtliff
Abstract: Inhibition of the transcription of genes in higher eukaryotic cells by inhibiting the activation of NF-KB, wherein the cells are treated with substances which specifically inhibit the proteolytic degradation of IKB-.alpha. directly or indirectly. Process for screening substances which inhibit NF-KB activation by inhibiting the proteolytic degradation of IKB-.alpha.. Use of the substances for treating pathological conditions which can be traced back to undesirable gene expression controlled by NF-KB.
Abstract: Cloning systems useful for the isolation of recombinant nucleic acid are disclosed in which the recombination of cloning-system nucleic acid and foreign nucleic acid is linked to the expression of a moiety on the surface of a host organism, the moiety being a first member of a binding pair. When recombination occurs between the nucleic acid and the foreign nucleic acid, the moiety is expressed on the surface of the host organism. The isolation of recombinant nucleic acid is then performed by attaching a second member of the binding pair to a solid support and contacting the host organism with the support. When the first member of the binding pair is expressed on the surface of the host organism, the host organism binds to the second member of the binding pair attached to the solid support, thereby selectively isolating those organisms.
Type:
Grant
Filed:
February 2, 1999
Date of Patent:
July 18, 2000
Assignee:
The Perkin-Elmer Corporation
Inventors:
John A. Bridgham, John Brandis, John Leong, Paul D. Hoeprich, Jr., Charles L. Sloan, Roger A. O'Neill
Abstract: The functional domains of Elongin A having transcriptional activation activity and Elongin BC binding activity and the functional domains of Elongin C having Elongin A activation activity and Elongin A and/or Elongin C binding activity have now been identified and isolated.
Abstract: Methods of detecting the presence of linear DNA in a sample that contains circular DNA are disclosed. The methods comprise combining an ATP-dependent deoxyribonuclease, ATP and a sample to form a reaction mixture, maintaining the reaction mixture under conditions in which linear DNA is processed by the ATP-dependent deoxyribonuclease, and detecting the presence of ADP thus produced. Methods of detecting the presence of DNA, RNA, or protein in samples are disclosed. The methods comprise combining an ATP-dependent deoxyribonuclease, an ATP-dependent ribonuclease, or an ATP-dependent protease, respectively, with ATP and a sample to form a reaction mixture. The reaction mixture is maintained under conditions in which DNA, RNA or protein is processed by the respective ATP-dependent enzyme. The presence of ADP thus produced is detected, indicating the presence of the enzyme substrate. Methods of quantifying the DNA molecules, RNA molecules or protein molecules are also disclosed.
Abstract: The present invention involves the creation of defined chromosomal deficiencies, inversions and duplications using Cre recombinase in ES cells transmitted into the mouse germ line. These chromosomal reconstructions can extend up to 3-4 cM. Chromosomal rearrangements are the major cause of inherited human disease and fetal loss. Additionally, translocations and deletions are recognized as major genetic changes that are causally involved in neoplasia. Chromosomal variants such as deletions and inversions are exploited commonly as genetic tools in organisms such as Drosophila. Mice with defined regions of segmental haploidy are useful for genetic screening and allow accurate models of human chromosomal diseases to be generated.
Type:
Grant
Filed:
June 26, 1997
Date of Patent:
June 20, 2000
Inventors:
Allan Bradley, Ramiro Ramirez-Solis, Pentao Liu, Hong Su, Binhai Zheng
Abstract: This invention provides an isolated, vertebrate nucleic acid molecule encoding the normal protein that prevents development of Wilson's disease. This invention also provides a nucleic acid molecule comprising a nucleic acid molecule of at least 15 nucleotides capable of specifically hybridizing with a sequence included within the sequence of the above-described nucleic acid molecule. Finally, this invention provides various uses of the isolated Wilson's disease gene.
Type:
Grant
Filed:
June 17, 1996
Date of Patent:
May 30, 2000
Assignees:
The Trustees of Columbia University in the City of New York, General Hospital Corporation